Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2006; 12(37): 6032-6036
Published online Oct 7, 2006. doi: 10.3748/wjg.v12.i37.6032
Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated withchemo-radiotherapy
RN Zárate R, F Arias, E Bandres, E Cubedo, R Malumbres, J García-Foncillas
RN Zárate R, E Bandres, E Cubedo, R Malumbres, J García-Foncillas, Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, 36 Pio XII Ave, Pamplona 31008, Spain
F Arias, Navarra Hospital center, s/n Irunlarrea Street, Pamplona 31008, Spain
Supported by a grant from the Navarra Government 70/2004
Correspondence to: Ruth Zárate, PhD, Laboratory of Biotechnology, University Clinic of Navarra, 36 Pio XII Ave, Pamplona 31008, Spain. rzarate@unav.es
Telephone: +34-948-255400-1127 Fax: +34-948-296795
Received: June 7, 2006
Revised: June 22, 2006
Accepted: July 7, 2006
Published online: October 7, 2006

AIM: To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer.

METHODS: We used PCR-RFLP to evaluate the genetic XPD Lys751Gln polymorphisms in 44 patients with stage III (48%) and IV (20%) gastric cancer treated with surgery following radiation therapy plus 5-fluorouracil/leucovorin based chemotherapy.

RESULTS: Statistical analysis showed that 75% (12 of 16) of relapse patients showed Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism was an independent predictor of high-risk relapse-free survival from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P = 0.036) and Kaplan-Meir test (P = 0.027, log-rank test).

CONCLUSION: XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to chemo-radiotherapy in resected gastric cancer patients.

Keywords: Xeroderma pigmentosum group D gene, Polymorphism, Gastric cancer, Radiotherapy